GLMD Stock Chart

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company that provides oral therapy for the treatment of non-alcoholic steatohepatitis (NASH). It develops Aramchol, a liver-targeted stearoyl-coenzyme A desaturase‑1 (SCD1) modulator with a dual mode of action on liver fibrosis, down regulation of steatosis, and a direct effect on hepatic stellate cells (HSCs).